Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Collegium Pharmaceutical, Inc is a drug manufacturers—specialty & generic business based in the US. Collegium Pharmaceutical shares (COLL) are listed on the NASDAQ and all prices are listed in US Dollars. Collegium Pharmaceutical employs 255 staff and has a trailing 12-month revenue of around USD$301.7 million.
Since the stock market crash in March caused by coronavirus, Collegium Pharmaceutical's share price has had significant negative movement.
Its last market close was USD$19.02, which is 20.52% down on its pre-crash value of USD$23.93 and 46.31% up on the lowest point reached during the March crash when the shares fell as low as USD$13.
If you had bought USD$1,000 worth of Collegium Pharmaceutical shares at the start of February 2020, those shares would have been worth USD$665.67 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$910.87.
|Latest market close||USD$19.02|
|52-week range||USD$11.19 - USD$25.59|
|50-day moving average||USD$19.8431|
|200-day moving average||USD$19.0906|
|Wall St. target price||USD$28|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.001|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||2.59%|
|1 month (2020-10-29)||5.43%|
|3 months (2020-08-28)||4.51%|
|6 months (2020-05-29)||-13.74%|
|1 year (2019-11-29)||-12.47%|
|2 years (2018-11-29)||0.21%|
|3 years (2017-11-29)||19.92%|
|5 years (2015-11-27)||0.11%|
Valuing Collegium Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Collegium Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Collegium Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$48.1 million.
The EBITDA is a measure of a Collegium Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$301.7 million|
|Operating margin TTM||4.26%|
|Gross profit TTM||USD$103 million|
|Return on assets TTM||1.7%|
|Return on equity TTM||0.16%|
|Market capitalisation||USD$703.6 million|
TTM: trailing 12 months
There are currently 4.4 million Collegium Pharmaceutical shares held short by investors – that's known as Collegium Pharmaceutical's "short interest". This figure is 3.7% up from 4.2 million last month.
There are a few different ways that this level of interest in shorting Collegium Pharmaceutical shares can be evaluated.
Collegium Pharmaceutical's "short interest ratio" (SIR) is the quantity of Collegium Pharmaceutical shares currently shorted divided by the average quantity of Collegium Pharmaceutical shares traded daily (recently around 328162.44377811). Collegium Pharmaceutical's SIR currently stands at 13.34. In other words for every 100,000 Collegium Pharmaceutical shares traded daily on the market, roughly 13340 shares are currently held short.
However Collegium Pharmaceutical's short interest can also be evaluated against the total number of Collegium Pharmaceutical shares, or, against the total number of tradable Collegium Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Collegium Pharmaceutical's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Collegium Pharmaceutical shares in existence, roughly 130 shares are currently held short) or 0.1477% of the tradable shares (for every 100,000 tradable Collegium Pharmaceutical shares, roughly 148 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Collegium Pharmaceutical.
Find out more about how you can short Collegium Pharmaceutical stock.
We're not expecting Collegium Pharmaceutical to pay a dividend over the next 12 months.
Over the last 12 months, Collegium Pharmaceutical's shares have ranged in value from as little as $11.19 up to $25.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Collegium Pharmaceutical's is 1.0044. This would suggest that Collegium Pharmaceutical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.